Optimizing Immunosuppression, Precision Medicine, and Big Data: The Required Path for Innovation in TransplantationPremiere Date: Tuesday, July 24, 2018
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, July 24, 2019
|Flavio Vincenti, MD (Moderator)
Professor of Clinical Medicine and Surgery
Medical Director, Kidney-Pancreas Program
University of California San Francisco
San Francisco, CA
|Dorry Segev, MD, PhD
Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology
Associate Vice Chair, Department of Surgery
Director, Epidemiology Research Group in Organ Transplantation
Johns Hopkins University
The optimization of immunosuppression is an important modifiable risk factor that can have a positive impact on long-term outcomes in transplantation. Breakthroughs in transplant procedures and the development of more effective immunosuppressive therapies have improved patient outcomes, with short-term survival rates over 80%. However, by five years post-transplant, up to 25% of patients have returned to dialysis, and 50% of all grafts fail within 10 years. Emerging literature that supports minimization or elimination of CNI therapy while maintaining optimal levels of immunosuppression, may offer new strategies for post-transplant immunosuppression.
Transplant medicine is moving toward a future of precision medicine that will improve long-term patient outcomes. How success in transplant is defined in 2018 may look much different from what will define success in 2025. Join experts Dr. Vincenti and Dr. Segev as they translate the dynamics of immunosuppression optimization, precision medicine, and the impact of big data on the future of transplant medicine.
At the end of this CE activity, participants should be able to:
- Identify modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
- Integrate strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
- Explore the impact of big data on precision medicine and the future of transplant medicine.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Differentiate between modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
- Assess strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
- Analyze the impact of big data on precision medicine and the future of transplant medicine.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Transplant surgeons, nephrologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat transplant patients.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Segev reports that he receives speaker honoraria for sanofi-aventis U.S. LLC, and Novartis Pharmaceuticals Corporation for lectures unrelated to their products.
Dr. Vincenti reports that he receives research support from Angion Biomedica Corp.; Astellas Pharma US, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Sharon Tordoff(planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).